Épidémiologie des néoplasies vulvaires intraépithéliales

Akerman, G.; Dussour, C.; Haddad, Bassam; Paniel, B. J.; Rouzier, Roman

doi:10.1016/j.gyobfe.2007.10.009

Cited by 23 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A 4400% increase in the incidence of VIN has been reported between 1973 and 2000, whereas the corresponding increase in incidence of vulval cancer has only been 20% (Akerman et al, 2007). This probably reflects an increasing incidence of human papillomavirus (HPV) high-risk type genital tract infections, as the most common type of VIN (usual or undifferentiated) shows over 85% HPV positivity, with type 16 DNA being detected in 75% of high-grade VIN (De Vuyst et al, 2009).…”

mentioning

confidence: 99%

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Vulval intraepithelial neoplasia (VIN) is a premalignant condition, which is frequently associated with type HPV16 infection, and multifocal disease has high rates of surgical treatment failure. METHODS: We report a phase II clinical trial of the topical immunomodulator, imiquimod, for 8 weeks, followed by 3 doses (weeks 10, 14 and 18) of therapeutic human papillomavirus (HPV) vaccination (TA-CIN, fusion protein HPV16 E6E7L2) in 19 women with VIN grades 2 and 3. Histology and HPV testing of biopsies were performed at weeks 0, 10, 20 and 52. Intralesional infiltration of T-cell subsets and lymphocyte proliferation for HPV systemic immune responses were also assessed. RESULTS: Lesion response (complete regression of VIN on histology) was observed in 32% (6 out of 19) of women at week 10, increasing to 58% (11 out of 19) at week 20 and 63% (12 out of 19) at week 52. At this time, 36% (5 out of 14) of lesions showed HPV16 clearance and 79% (15 out of 19) of women were symptom free. At week 20, after treatment with imiquimod and vaccination, there was significantly increased local infiltration of CD8 and CD4 T cells in lesion responders; in contrast, nonresponders (persistent VIN by histology) showed an increased density of T regulatory cells. After vaccination, only lesion responders had significantly increased lympho-proliferation to the HPV vaccine antigens. CONCLUSION: The therapeutic effect of treatment depends on the differential immune response of responders and non-responders with affect locally and systemically.

show abstract

mentioning

confidence: 99%

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Alors que l'é volution des CIN vers la pathologie carcinomateuse é pidermoïde est quasiment toujours lié e à l'infection par HPV, seuls 30 à 40 % des carcinomes é pidermoïdes invasif vulvaires sont lié s à une infection à HPV [1].…”

Section: Dé Finitions Et Terminologieunclassified

“…Aux É tats-Unis, les registres é pidé miologiques ont mis en é vidence une augmentation de plus de 400 % de l'incidence des VIN entre 1973 et 2000 [1].…”

Section: Introductionunclassified

Traitement des néoplasies vulvaires intra-épithéliales par imiquimod

Paternotte

Hébert

Ouldamer

et al. 2015

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

“…The risk of progression from HSIL to VSCC is low and ranges from 3 to 16%, while for dVIN it reaches 32.8% [5]. In the United States, between 1973 and 2000, the incidence of vulvar precancers increased by 411% in contrast with increase of 20% for invasive cancers [6] reaching the reported incidence of precancers of 2.86 per 100,000 women in 2000 [7]. Of patients diagnosed with these disorders, 75% are below 50 years of age [7].…”

Section: Introductionmentioning

confidence: 99%

Circulating Hsa-miR-431-5p as Potential Biomarker for Squamous Cell Vulvar Carcinoma and Its Premalignant Lesions

et al. 2021

View full text Add to dashboard Cite

Vulvar squamous cell carcinoma (VSCC) develops from high-grade squamous intraepithelial lesions (HSIL) and differentiated vulvar intraepithelial neoplasia (dVIN). This study aimed to assess the diagnostic value of circulating hsa-miR-431-5p in vulvar precancers and VSCC. Expression levels of hsa-miR-431-5p were analyzed by quantitative RT-PCR in plasma samples of 29 patients with vulvar precancers (HSIL or dVIN), 107 with VSCC as well as 15 healthy blood donors. We used hsa-miR-93-5p and hsa-miR-425-5p as normalizers. The levels of miR-431-5p were increased in the blood of patients with VSCC compared to those with vulvar precancers. Statistically significant differences in the survival rates (time to progression) were revealed for VSCC patients categorized by miR-431-5p levels. Low levels of circulating miR-431-5p were found to be indicative of unfavorable survival rates. In summary, our data reveal the diagnostic potential of circulating miR-431-5p in patients with vulvar precancers and VSCC.

show abstract

Épidémiologie des néoplasies vulvaires intraépithéliales

Cited by 23 publications

References 18 publications

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

Traitement des néoplasies vulvaires intra-épithéliales par imiquimod

Circulating Hsa-miR-431-5p as Potential Biomarker for Squamous Cell Vulvar Carcinoma and Its Premalignant Lesions

Contact Info

Product

Resources

About